Ping An Biomedical (MJID) appoints new CEO, CFO amid board exits

Ping An Biomedical Co., Ltd. announced a major leadership transition.

Rhea-AI Filing Summary

Ping An Biomedical Co., Ltd. announced a major leadership transition. In October 2025, the Board accepted the immediate resignations of its Chair (Ms. Yuk Yin Judy Li), Chief Executive Officer and Director (Ms. Lina Jiang), Chief Financial Officer (Ms. Xueyuan Chen), and an independent director (Mr. Taylor Carl Coplen). The company stated each resigned for personal reasons and not due to any disagreement with the company or Board on operations, policies, or practices.

New leadership was appointed effective October 14, 2025. Mr. Pijun Liu was named Chairman, Chief Executive Officer, and Executive Director; Ms. Hongli Yang was appointed Chief Financial Officer; and Mr. Xianzhi Liu joined as an independent director. The filing includes brief professional backgrounds for each appointee.

Insights

Corporate governance analyst

Substantial board and C‑suite turnover with same‑day replacements.

Multiple top leaders resigned effective immediately, including the Chair, CEO, CFO, and an independent director. The company states these departures were for personal reasons and without disagreements on operations, policies, or practices. Such breadth of change concentrates attention on continuity of governance and execution.

The Board simultaneously appointed a new Chairman/CEO/Executive Director (Mr. Pijun Liu), a new CFO (Ms. Hongli Yang), and a new independent director (Mr. Xianzhi Liu) effective October 14, 2025. This places key responsibilities with newly named leaders from day one.

Actual operational impact will hinge on how quickly the new team aligns on strategy and controls. Subsequent disclosures may provide updates on priorities and any committee or policy changes adopted after October 14, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did Ping An Biomedical (MJID) disclose?

The Board accepted immediate resignations of the Chair, CEO/Director, CFO, and an independent director, and appointed a new CEO/Chair, CFO, and independent director.

Who are the new executives at Ping An Biomedical (MJID) and when were they appointed?

Effective October 14, 2025, Mr. Pijun Liu became Chairman/CEO/Executive Director, Ms. Hongli Yang became CFO, and Mr. Xianzhi Liu became an independent director.

Why did the departing leaders of Ping An Biomedical (MJID) resign?

Each resigned for personal reasons and not due to any disagreement with the company or Board on operations, policies, or practices.

Which directors and officers resigned from Ping An Biomedical (MJID)?

Ms. Yuk Yin Judy Li (Chair/Director), Ms. Lina Jiang (CEO/Director), Ms. Xueyuan Chen (CFO), and Mr. Taylor Carl Coplen (independent director).

What roles did Mr. Pijun Liu assume at Ping An Biomedical (MJID)?

He was appointed Chairman of the Board, Chief Executive Officer, and Executive Director effective October 14, 2025.

Does the filing indicate any disagreements behind the resignations at Ping An Biomedical (MJID)?

No. It states there were no disagreements with the company or Board regarding operations, policies, or practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 06:04 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025

Commission File Number: 001-42155

Ping An Biomedical Co., Ltd.

(Registrant’s Name)

22/F, China United Plaza, 1002-1008, Tai Nan West Street,

Cheung Sha Wan, Kowloon, Hong Kong

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Resignation of Chairman, Chief Executive Officer, Chief Financial Officer, Executive Director and Independent Directors

In October 2025, the Board of Directors (the “Board”) of Ping An Biomedical Co., Ltd. (the “Company”) received and accepted the resignation of Ms. Yuk Yin Judy Li from her position as the Chairman and Director of the Board of the Company, the resignation of Ms. Lina Jiang from her position as the Director of the Board and Chief Executive Officer of the Company, the resignation of Ms. Xueyuan Chen from her position as the Chief Financial Officer of the Company and Mr. Taylor Carl Coplen from his position as independent director of the Board, all effective immediately. Each of Ms. Yuk Yin Judy Li, Ms. Lina Jiang, Ms. Xueyuan Chen and Mr. Taylor Carl Coplen resigned for personal reasons and not due to any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, or practices.

Appointment of Chairman, Chief Financial Officer, Executive Director and Independent Director

Effective October 14, 2025, the Board appointed Mr. Pijun Liu as a Chairman of the Board of the Company, Chief Executive Officer of the Company, and the Executive Director of the Board, Ms. Hongli Yang as a Chief Financial Officer of the Company and Mr. Xianzhi Liu as independent director of the Board.

Mr. Pijun Liu, male, born in 1982, holds Chinese nationality. He graduated from Wuhan University of Technology with a bachelor’s degree and earned a master’s degree in Computer and Information Technology from the University of Arizona in the United States. From 2018 to 2020, he pursued postgraduate studies at the School of Finance, Renmin University of China, and later attended the EMBA program at Tsinghua Five College of Economics and Management. From 2004 to 2007, served as a project manager at ELong.com. From 2014 to 2023, served as the founder and CEO of Yueshang Group, receiving investments.

Ms. Hongli Yang, female, was born in 1995 and holds Chinese nationality. She graduated from Xiangtan University, majoring in Financial Management, and obtained a bachelor’s degree. Since 2021, she has successively served as the Chief Financial Officer at Softcom Information Technology (Group) Co., Ltd., Beijing Sinobo Information Technology Co., Ltd., and Huibo Cloud Communication Technology Co., Ltd. In these positions, she has comprehensively coordinated the management work of the finance department.

Mr. Xianzhi Liu, male, born in 1997, is a Chinese national with no permanent residence abroad. He graduated from North University of China with a bachelor’s degree in Electronic Science and Technology and from the University of Leeds with a master’s degree in Mechatronics and Robotics. In 2022, he worked at JD.com, Inc. From 2023 to 2024, he was employed at Beijing New Oriental Education Consulting Co., Ltd. Since 2025, he has been working at New Channel (Zhejiang Headquarters).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PING AN BIOMEDICAL CO., LTD.
Date: October 14, 2025	By:	/s/ Pijun Liu
	Name:	Pijun Liu
	Title:	Chairman of the Board of Directors

2